Agilis Biotherapeutics LLC, of Cambridge, Mass., said it has been selected by the National Center for Accelerating Translational Sciences (NCATS) as an awardee of a cooperative research and development agreement (CRADA) under the National Institutes of Health’s (NIH) Therapeutics for Rare and Neglected Diseases (TRND) program.